Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

Alan Breier, Virginia K. Sutton, Peter D. Feldman, Deborah L. Kadam, Iris Ferchland, Padraig Wright, Joseph H. Friedman

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Background: Studies in elderly patients demonstrate antipsychotic efficacy and favorable safety profiles for olanzapine. We report results from two placebo-controlled, double-blind studies of olanzapine for treatment of dopamimetic drug-induced psychosis in patients with Parkinson's disease (PD). Methods: Patients were treated with olanzapine or placebo for 4 weeks while dopamimetic therapy was held constant. Olanzapine was initiated at 2.5 mg/day, with 2.5-mg/day increases allowed every 3 to 4 days up to the maximum dose of 15 mg/day. Results: Olanzapine patients showed significant improvements from baseline on positive symptoms and most efficacy measures, but no significant treatment-group differences were observed. Olanzapine performed significantly worse than placebo in both studies on the Unified Parkinson's Disease Rating Scale (UPDRS) total, Motor, and Activities of Daily Living scales, but not the UPDRS Tremor item or Complications scores. Corrected QT interval, vital signs, and body weight were not significantly different from placebo. Conclusions: These findings did not demonstrate superior efficacy of olanzapine for treatment of dopamimetic-induced psychosis in PD. The initial dose-titration schedule and mild baseline levels of psychosis may account for these findings. Future studies involving gradual dose titration are needed to explore further olanzapine's optimum use for patients with PD with treatment-related psychosis.

Original languageEnglish (US)
Pages (from-to)438-445
Number of pages8
JournalBiological Psychiatry
Volume52
Issue number5
DOIs
StatePublished - Sep 1 2002

Fingerprint

olanzapine
Psychotic Disorders
Parkinson Disease
Placebos
Therapeutics
Substance-Induced Psychoses
Vital Signs
Tremor
Activities of Daily Living
Double-Blind Method
Antipsychotic Agents

Keywords

  • Dopamimetic psychosis
  • Extrapyramidal symptoms
  • Olanzapine
  • Parkinson's disease

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Breier, A., Sutton, V. K., Feldman, P. D., Kadam, D. L., Ferchland, I., Wright, P., & Friedman, J. H. (2002). Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biological Psychiatry, 52(5), 438-445. https://doi.org/10.1016/S0006-3223(02)01392-6

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. / Breier, Alan; Sutton, Virginia K.; Feldman, Peter D.; Kadam, Deborah L.; Ferchland, Iris; Wright, Padraig; Friedman, Joseph H.

In: Biological Psychiatry, Vol. 52, No. 5, 01.09.2002, p. 438-445.

Research output: Contribution to journalArticle

Breier, A, Sutton, VK, Feldman, PD, Kadam, DL, Ferchland, I, Wright, P & Friedman, JH 2002, 'Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease', Biological Psychiatry, vol. 52, no. 5, pp. 438-445. https://doi.org/10.1016/S0006-3223(02)01392-6
Breier, Alan ; Sutton, Virginia K. ; Feldman, Peter D. ; Kadam, Deborah L. ; Ferchland, Iris ; Wright, Padraig ; Friedman, Joseph H. / Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. In: Biological Psychiatry. 2002 ; Vol. 52, No. 5. pp. 438-445.
@article{a11528b7ef7a47d782b4d4b162850a66,
title = "Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease",
abstract = "Background: Studies in elderly patients demonstrate antipsychotic efficacy and favorable safety profiles for olanzapine. We report results from two placebo-controlled, double-blind studies of olanzapine for treatment of dopamimetic drug-induced psychosis in patients with Parkinson's disease (PD). Methods: Patients were treated with olanzapine or placebo for 4 weeks while dopamimetic therapy was held constant. Olanzapine was initiated at 2.5 mg/day, with 2.5-mg/day increases allowed every 3 to 4 days up to the maximum dose of 15 mg/day. Results: Olanzapine patients showed significant improvements from baseline on positive symptoms and most efficacy measures, but no significant treatment-group differences were observed. Olanzapine performed significantly worse than placebo in both studies on the Unified Parkinson's Disease Rating Scale (UPDRS) total, Motor, and Activities of Daily Living scales, but not the UPDRS Tremor item or Complications scores. Corrected QT interval, vital signs, and body weight were not significantly different from placebo. Conclusions: These findings did not demonstrate superior efficacy of olanzapine for treatment of dopamimetic-induced psychosis in PD. The initial dose-titration schedule and mild baseline levels of psychosis may account for these findings. Future studies involving gradual dose titration are needed to explore further olanzapine's optimum use for patients with PD with treatment-related psychosis.",
keywords = "Dopamimetic psychosis, Extrapyramidal symptoms, Olanzapine, Parkinson's disease",
author = "Alan Breier and Sutton, {Virginia K.} and Feldman, {Peter D.} and Kadam, {Deborah L.} and Iris Ferchland and Padraig Wright and Friedman, {Joseph H.}",
year = "2002",
month = "9",
day = "1",
doi = "10.1016/S0006-3223(02)01392-6",
language = "English (US)",
volume = "52",
pages = "438--445",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

AU - Breier, Alan

AU - Sutton, Virginia K.

AU - Feldman, Peter D.

AU - Kadam, Deborah L.

AU - Ferchland, Iris

AU - Wright, Padraig

AU - Friedman, Joseph H.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Background: Studies in elderly patients demonstrate antipsychotic efficacy and favorable safety profiles for olanzapine. We report results from two placebo-controlled, double-blind studies of olanzapine for treatment of dopamimetic drug-induced psychosis in patients with Parkinson's disease (PD). Methods: Patients were treated with olanzapine or placebo for 4 weeks while dopamimetic therapy was held constant. Olanzapine was initiated at 2.5 mg/day, with 2.5-mg/day increases allowed every 3 to 4 days up to the maximum dose of 15 mg/day. Results: Olanzapine patients showed significant improvements from baseline on positive symptoms and most efficacy measures, but no significant treatment-group differences were observed. Olanzapine performed significantly worse than placebo in both studies on the Unified Parkinson's Disease Rating Scale (UPDRS) total, Motor, and Activities of Daily Living scales, but not the UPDRS Tremor item or Complications scores. Corrected QT interval, vital signs, and body weight were not significantly different from placebo. Conclusions: These findings did not demonstrate superior efficacy of olanzapine for treatment of dopamimetic-induced psychosis in PD. The initial dose-titration schedule and mild baseline levels of psychosis may account for these findings. Future studies involving gradual dose titration are needed to explore further olanzapine's optimum use for patients with PD with treatment-related psychosis.

AB - Background: Studies in elderly patients demonstrate antipsychotic efficacy and favorable safety profiles for olanzapine. We report results from two placebo-controlled, double-blind studies of olanzapine for treatment of dopamimetic drug-induced psychosis in patients with Parkinson's disease (PD). Methods: Patients were treated with olanzapine or placebo for 4 weeks while dopamimetic therapy was held constant. Olanzapine was initiated at 2.5 mg/day, with 2.5-mg/day increases allowed every 3 to 4 days up to the maximum dose of 15 mg/day. Results: Olanzapine patients showed significant improvements from baseline on positive symptoms and most efficacy measures, but no significant treatment-group differences were observed. Olanzapine performed significantly worse than placebo in both studies on the Unified Parkinson's Disease Rating Scale (UPDRS) total, Motor, and Activities of Daily Living scales, but not the UPDRS Tremor item or Complications scores. Corrected QT interval, vital signs, and body weight were not significantly different from placebo. Conclusions: These findings did not demonstrate superior efficacy of olanzapine for treatment of dopamimetic-induced psychosis in PD. The initial dose-titration schedule and mild baseline levels of psychosis may account for these findings. Future studies involving gradual dose titration are needed to explore further olanzapine's optimum use for patients with PD with treatment-related psychosis.

KW - Dopamimetic psychosis

KW - Extrapyramidal symptoms

KW - Olanzapine

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0036752109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036752109&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(02)01392-6

DO - 10.1016/S0006-3223(02)01392-6

M3 - Article

VL - 52

SP - 438

EP - 445

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 5

ER -